Positive results from KEYNOTE-091 study in adjuvant therapy for stage IB-IIIA lung cancer

Article source: Medicine Rubik's Cube Med

Author: Zisu

On January 10, Merck announced that the Phase III KEYNOTE-091 study met one of its dual primary endpoints

For people with high PD-L1 expression (TPS score ≥50%), adjuvant Keytruda treatment also observed an improvement in DFS compared with the placebo group, but according to the predetermined statistical analysis method, this endpoint did not reach statistical significance.

Keytruda demonstrated a favorable safety profile in the KEYNOTE-091 study, and the safety results were consistent with previous studies

KEYNOTE-091 is a randomized, controlled clinical trial evaluating the efficacy and safety of Keytruda versus placebo with or without adjuvant chemotherapy as adjuvant therapy in patients with stage IB-IIIA NSCLC after surgical resection (lobectomy or pneumonectomy) difference

At present, immunotherapy has gradually become the back-line and even the first-line therapy for major cancer types, and the earlier and longer clinical use has become a new battlefield for companies to develop PD1/PD-L1 drugs

Note: The original text has been deleted